Total Articles:
886,158 Total Authors:
151,791 Total Downloads:
19,356,238
Newest Member Malka Ladick
Text Ad's
Fluoroquinolone Antibiotics Classification, Uses and Unwanted effects The fluoroquinolones absolutely are a relatively new group of antibiotics. Fluoroquinolones were first introduced in 1986, but they also are really modified quinolones, a category of an
The fluoroquinolones are an order of synthetic, broad-spectrum antibacterial agents with bactericidal activity. The parent of a typical group is nalidixic acid, sourced out of 1962 by Lescher and colleagues. The very first fluoroquinolones were usually mainly because they were the one orally administered agents available for the treatment of serious infections attributable to gram-negative organisms, including Pseudomonas species.
The newer fluoroquinolones have got a wider clinical use along with a broader spectrum of antibacterial activity including gram-positive and gram-negative aerobic and anaerobic organisms. Some of the newer fluoroquinolones contain an important role in managing community-acquired pneumonia and intra-abdominal infections.
Fluoroquinolones disadvantages:
Tendonitis or tendon rupture
Multiple drug interactions
Not used in children
Newer quinolones produce additional toxicities into the heart have been not found with the older agents
Fluoroquinolones advantages:
Ease in administration
Daily or twice daily dosing
Excellent oral absorption
Excellent tissue penetration
Prolonged half-lives
Significant entry into phagocytic cells
Efficacy
Overall safety
Classification of Fluoroquinolones
Being a group, the fluoroquinolones have excellent in vitro activity against a large variety of both gram-positive and gram-negative bacteria. The present fluoroquinolones have enhanced activity against gram-positive bacteria with just the a decreased reduction in activity against gram-negative bacteria. Their expanded gram-positive activity is very important since it includes significant activity against Streptococcus pneumoniae.
First Generation. The first-generation agents include cinoxacin and nalidixic acid, which are the oldest and least often used quinolones. These drugs had poor systemic distribution and limited activity and were utilized primarily for gram-negative urinary tract infections. Cinoxacin and nalidixic acid require more frequent dosing compared to the newer quinolones, plus they are also more susceptible to your development of bacterial resistance.
Second Generation. The second-generation fluoroquinolones have increased gram-negative activity, along with some gram-positive and atypical pathogen coverage. When compared with first-generation quinolones, these drugs have broader clinical applications in the treatment of complicated urinary tract infections and pyelonephritis, sexually transmitted diseases, selected pneumonias and skin infections.
Second-generation agents include ciprofloxacin, enoxacin, lomefloxacin, norfloxacin and ofloxacin. Ciprofloxacin will probably be the most potent fluoroquinolone against P. aeruginosa. Ciprofloxacin and ofloxacin would be the hottest second-generation quinolones due to availability in oral and intravenous formulations and also their broad pair of FDA-labeled indications.
Third Generation. The third-generation fluoroquinolones are separated with a third class because of their expanded activity against gram-positive organisms, particularly penicillin-sensitive and penicillin-resistant S. pneumoniae, and atypical pathogens for example Mycoplasma pneumoniae and Chlamydia pneumoniae. Despite the fact that the third-generation agents retain broad gram-negative coverage, they're less active than ciprofloxacin against Pseudomonas species.
Because of their expanded antimicrobial spectrum, third-generation fluoroquinolones are of help in the treatment of community-acquired pneumonia, acute sinusitis and acute exacerbations of chronic bronchitis, that happen to be their primary FDA-labeled indications. The third-generation fluoroquinolones include levofloxacin, gatifloxacin, moxifloxacin and sparfloxacin.
Fourth Generation. The fourth-generation fluoroquinolones add significant antimicrobial activity against anaerobes while maintaining the gram-positive and gram-negative workings of the third-generation drugs. Additionally they retain activity against Pseudomonas species similar to that of ciprofloxacin. The fourth-generation fluoroquinolones include trovafloxacin (Trovan).
On account of worry about hepatotoxicity, trovafloxacin therapy really should be ready for life- or limb-threatening infections requiring inpatient treatment (hospital or long-term care facility), along with the drug is critical for not than 14 days.
Unwanted effects
The fluoroquinolones as a class are generally well tolerated. Most uncomfortable side effects are mild in severity, self-limited, and rarely induce treatment discontinuation. However, they often have serious adverse effects.
Fluoroquinolones are approved for use only in people older than 18. They often affect the growth of bones, teeth, and cartilage inside a child or fetus. The FDA has assigned fluoroquinolones to pregnancy risk category C, indicating when these drugs have the potential to cause teratogenic or embryocidal effects. Giving fluoroquinolones during pregnancy will not be recommended unless the benefits justify the potential risks into the fetus. These agents are also excreted in breast milk and may even be bypassed during breast-feeding whether possible.
Gastrointestinal effects. A typical adverse events familiar with fluoroquinolone administration are gastrointestinal (nausea, vomiting, diarrhea, constipation, and abdominal pain), which occur approx 1 to 5% of patients.
CNS effects. Headache, dizziness, and drowsiness are actually reported for all fluoroquinolones. Insomnia was reported in 3-7% of patients with ofloxacin. Severe CNS effects, including seizures, seem to have been reported in patients receiving trovafloxacin. Seizures may develop within 3 - 4 times of therapy but resolve with drug discontinuation. Although seizures are infrequent, fluoroquinolones should really be avoided in patients with a tradition of convulsion, cerebral trauma, or anoxia. No seizures have already been reported with levofloxacin, moxifloxacin, gatifloxacin, and gemifloxacin. In the older non-fluorinated quinolones neurotoxic symptoms for example dizziness occurred in about 50% of the patients.
Phototoxicity. Knowledge of ultraviolet A rays from directly or indirectly sunlight ought to be avoided during treatment and a few days (5 days with sparfloxacin) as the use of the drug. The degree of phototoxic potential of fluoroquinolones is often as follows: lomefloxacin > sparfloxacin > ciprofloxacin > norfloxacin = ofloxacin = levofloxacin = gatifloxacin = moxifloxacin.
Musculoskeletal effects. Concern about the introduction of musculoskeletal effects, evident in animal studies, has led to your contraindication of fluoroquinolones for routine use in children and in women who are pregnant or lactating.
Tendon damage (tendinitis and tendon rupture). Although fluoroquinolone-related tendinitis generally resolves within one week of discontinuation of therapy, spontaneous ruptures have already been reported provided nine months after cessation of fluoroquinolone use. Potential risk factors for tendinopathy include age >50 years, male gender, and concomitant utilization of corticosteroids.
Hepatoxicity. Trovafloxacin use has long been linked to rare liver damage, which prompted the withdrawal of many oral preparations coming from the U.S. market. However, the IV preparation is readily available for remedy for infections so serious that the benefits outweigh the risks.
Cardiovascular effects. The newer quinolones are actually found to supply additional toxicities to the heart that were not found together with the older compounds. Evidence means that sparfloxacin and grepafloxacin could have essentially the most cardiotoxic potential.
Hypoglycemia/Hyperglycemia. Recently, rare cases of hypoglycemia have been reported with gatifloxacin and ciprofloxacin in patients also receiving oral diabetic medications, primarily sulfonylureas. Although hypoglycemia is reported with other fluoroquinolones (levofloxacin and moxifloxacin), the results have already been mild.
Hypersensitivity. Hypersensitivity reactions occur hardly during quinolone therapy and can be mild to moderate in severity, and typically resolve after treatment is stopped.
Conditions treated with Fluoroquinolones: indications and uses
The newer fluoroquinolones possess a wider clinical use and a broader spectrum of antibacterial activity including gram-positive and gram-negative aerobic and anaerobic organisms. Some of the newer fluoroquinolones posses important part in treating community-acquired pneumonia and intra-abdominal infections. The serum elimination half-life of the fluoroquinolones range from 3 -20 hours, allowing for maybe once or twice daily dosing.
Author Resource:-
The fluoroquinolones are a breed of synthetic, broad-spectrum antibacterial agents with bactericidal activity. The parent of many group is nalidixic acid, discovered in 1962 by Lescher and colleagues. The very first fluoroquinolones were usually mainly because they were the only orally administered agents available for the treatment of serious infections as a result of gram-negative organisms, including Pseudomonas species.
The newer fluoroquinolones possess a wider clinical use along with a broader spectrum of antibacterial activity including gram-positive and gram-negative aerobic and anaerobic organisms. A number of the newer fluoroquinolones contain an important role in managing community-acquired pneumonia and intra-abdominal infections.
Fluoroquinolones disadvantages:
Tendonitis or tendon rupture
Multiple drug interactions
Not used in children
Newer quinolones produce additional toxicities to the heart have been not found with the older brokers
Fluoroquinolones advantages:
Ease of administration
Daily or twice daily dosing
Excellent oral absorption
Excellent tissue penetration
Prolonged half-lives
Significant entry into phagocytic cells
Efficacy
Overall safety
Classification of Fluoroquinolones
As a group, the fluoroquinolones have excellent in vitro activity against a large choice of both gram-positive and gram-negative bacteria. Modern-day fluoroquinolones have enhanced activity against gram-positive bacteria with just the a decreased discount in activity against gram-negative bacteria. Their expanded gram-positive activity is very important as it includes significant activity against Streptococcus pneumoniae.
First Generation. The first-generation agents include cinoxacin and nalidixic acid, knowing the oldest and least often used quinolones. These drugs had poor systemic distribution and limited activity and were put to use primarily for gram-negative urinary tract infections. Cinoxacin and nalidixic acid require more frequent dosing than the newer quinolones, and they're more susceptible to the development of bacterial resistance.
Second Generation. The second-generation fluoroquinolones have increased gram-negative activity, as well as some gram-positive and atypical pathogen coverage. When compared to first-generation quinolones, these drugs have broader clinical applications within the treatment of complicated urinary tract infections and pyelonephritis, stds, selected pneumonias and skin infections.
Second-generation agents include ciprofloxacin, enoxacin, lomefloxacin, norfloxacin and ofloxacin. Ciprofloxacin would be the most potent fluoroquinolone against P. aeruginosa. Ciprofloxacin and ofloxacin would be the hottest second-generation quinolones owing to their availability in oral and intravenous formulations and the broad set of FDA-labeled indications.
Third Generation. The third-generation fluoroquinolones are separated into a third class owing to their expanded activity against gram-positive organisms, particularly penicillin-sensitive and penicillin-resistant S. pneumoniae, and atypical pathogens similar to Mycoplasma pneumoniae and Chlamydia pneumoniae. Even though third-generation agents retain broad gram-negative coverage, they are less active than ciprofloxacin against Pseudomonas species.
Due to expanded antimicrobial spectrum, third-generation fluoroquinolones are helpful inside the treatment of community-acquired pneumonia, acute sinusitis and acute exacerbations of chronic bronchitis, which you ll find are their primary FDA-labeled indications. The third-generation fluoroquinolones include levofloxacin, gatifloxacin, moxifloxacin and sparfloxacin.
Fourth Generation. The fourth-generation fluoroquinolones add significant antimicrobial activity against anaerobes while keeping the gram-positive and gram-negative activity of the third-generation drugs. Additionally retain activity against Pseudomonas species similar to that of ciprofloxacin. The fourth-generation fluoroquinolones include trovafloxacin (Trovan).
Due to worry about hepatotoxicity, trovafloxacin therapy ought to be kept for life- or limb-threatening infections requiring inpatient treatment (hospital or long-term care facility), and the drug is critical for no longer than 14 days.
Unwanted effects
The fluoroquinolones as a class quite some time well tolerated. Most adverse effects are mild in severity, self-limited, and infrequently set off treatment discontinuation. However, they can have serious adverse reactions.
Fluoroquinolones are approved for use only in people older than 18. They can affect the expansion of bones, teeth, and cartilage inside a child or fetus. The FDA has assigned fluoroquinolones to pregnancy risk category C, indicating these drugs have the potential to cause teratogenic or embryocidal effects. Giving fluoroquinolones during your pregnancy is not really recommended unless the advantages justify the new risks to your fetus. These agents can be excreted in breast milk and will be avoided during breast-feeding whether possible.
Gastrointestinal effects. The commonest side effects experienced with fluoroquinolone administration are gastrointestinal (nausea, vomiting, diarrhea, constipation, and abdominal pain), which occur in one to 5% of patients.
CNS effects. Headache, dizziness, and drowsiness are actually reported for all fluoroquinolones. Insomnia was reported in 3-7% of patients with ofloxacin. Severe CNS effects, including seizures, have been reported in patients receiving trovafloxacin. Seizures may develop within 3 to 4 times of therapy but resolve with drug discontinuation. Although seizures are infrequent, fluoroquinolones ought to be avoided in patients by using a history of convulsion, cerebral trauma, or anoxia. No seizures seem to have been reported with levofloxacin, moxifloxacin, gatifloxacin, and gemifloxacin. In the older non-fluorinated quinolones neurotoxic symptoms for instance dizziness happened about 50% of the patients.
Phototoxicity. Knowledge of ultraviolet A rays from directly or indirectly sunlight should really be avoided during treatment and several days (5 days with sparfloxacin) after the utilization of prescription. The degree of phototoxic potential of fluoroquinolones is often as follows: lomefloxacin > sparfloxacin > ciprofloxacin > norfloxacin = ofloxacin = levofloxacin = gatifloxacin = moxifloxacin.
Musculoskeletal effects. Concern about the creation of musculoskeletal effects, evident in animal studies, has led to the contraindication of fluoroquinolones for routine use in children whereas in the women who are pregnant or lactating.
Tendon damage (tendinitis and tendon rupture). Although fluoroquinolone-related tendinitis generally resolves within one week of discontinuation of therapy, spontaneous ruptures have already been reported provided nine months after cessation of fluoroquinolone use. Potential risk factors for tendinopathy include age >50 years, male gender, and concomitant use of corticosteroids.
Hepatoxicity. Trovafloxacin use has been connected with rare liver damage, which prompted the withdrawal of your oral preparations out of your U.S. market. However, the IV preparation continues to be an alternative for remedy for infections so serious the benefits outweigh the risks.
Cardiovascular effects. The newer quinolones have already been found to supply additional toxicities to the heart which were not found together with the older compounds. Evidence advices that sparfloxacin and grepafloxacin can have by far the most cardiotoxic potential.
Hypoglycemia/Hyperglycemia. Recently, rare cases of hypoglycemia seem to have been reported with gatifloxacin and ciprofloxacin in patients also receiving oral diabetic medications, primarily sulfonylureas. Although hypoglycemia has been reported with other fluoroquinolones (levofloxacin and moxifloxacin), the results have been mild.
Hypersensitivity. Hypersensitivity reactions occur hardly during quinolone therapy and tend to be mild to moderate in severity, and frequently resolve after treatment is stopped.
Conditions treated with Fluoroquinolones: indications and uses
The newer fluoroquinolones have got a wider clinical use as well as a broader spectrum of antibacterial activity including gram-positive and gram-negative aerobic and anaerobic organisms. A number of the newer fluoroquinolones have an important role in treating community-acquired pneumonia and intra-abdominal infections. The serum elimination half-life of a typical fluoroquinolones vary from 3 -20 hours, allowing for a few times daily dosing.
![[Valid RSS feed]](http://article2008.com/images/feed-icon.png "XML Feed For RSS"){kind=icon}
![[Valid RSS feed]](http://article2008.com/images/icon_Rss.png "XML Feed For RSS"){kind=icon}
Category Rss Feed
Print This Article
Add To Favorites